These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20398370)

  • 1. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.
    Campanella C; Mottolese M; Cianciulli A; Torsello A; Merola R; Sperduti I; Melucci E; Conti S; Diodoro MG; Zeuli M; Paoletti G; Cognetti F; Garufi C
    J Transl Med; 2010 Apr; 8():36. PubMed ID: 20398370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
    Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
    Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
    Scartozzi M; Bearzi I; Mandolesi A; Pierantoni C; Loupakis F; Zaniboni A; Negri F; Quadri A; Zorzi F; Galizia E; Berardi R; Biscotti T; Labianca R; Masi G; Falcone A; Cascinu S
    BMC Cancer; 2009 Aug; 9():303. PubMed ID: 19712476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis.
    Jiang Z; Li C; Li F; Wang X
    PLoS One; 2013; 8(2):e56205. PubMed ID: 23441167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
    Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer.
    Birkman EM; Avoranta T; Ålgars A; Korkeila E; Lintunen M; Lahtinen L; Kuopio T; Ristamäki R; Carpén O; Sundström J
    Hum Pathol; 2018 Dec; 82():163-171. PubMed ID: 30096327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.
    Ålgars A; Avoranta T; Österlund P; Lintunen M; Sundström J; Jokilehto T; Ristimäki A; Ristamäki R; Carpén O
    PLoS One; 2014; 9(6):e99590. PubMed ID: 24940619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
    Personeni N; Fieuws S; Piessevaux H; De Hertogh G; De Schutter J; Biesmans B; De Roock W; Capoen A; Debiec-Rychter M; Van Laethem JL; Peeters M; Humblet Y; Van Cutsem E; Tejpar S
    Clin Cancer Res; 2008 Sep; 14(18):5869-76. PubMed ID: 18794099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
    Gonçalves A; Esteyries S; Taylor-Smedra B; Lagarde A; Ayadi M; Monges G; Bertucci F; Esterni B; Delpero JR; Turrini O; Lelong B; Viens P; Borg JP; Birnbaum D; Olschwang S; Viret F
    BMC Cancer; 2008 Jun; 8():169. PubMed ID: 18544172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.
    Bengala C; Bettelli S; Bertolini F; Salvi S; Chiara S; Sonaglio C; Losi L; Bigiani N; Sartori G; Dealis C; Malavasi N; D'Amico R; Luppi G; Gatteschi B; Maiorana A; Conte PF
    Ann Oncol; 2009 Mar; 20(3):469-74. PubMed ID: 19095777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
    Cappuzzo F; Finocchiaro G; Rossi E; Jänne PA; Carnaghi C; Calandri C; Bencardino K; Ligorio C; Ciardiello F; Pressiani T; Destro A; Roncalli M; Crino L; Franklin WA; Santoro A; Varella-Garcia M
    Ann Oncol; 2008 Apr; 19(4):717-23. PubMed ID: 17974556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
    Hörndler C; Gallego R; García-Albeniz X; Alonso-Espinaco V; Alonso V; Escudero P; Jimeno M; Ortego J; Codony-Servat J; Fernández-Martos C; Calatrava A; Marín-Aguilera M; Muñoz J; Castellví-Bel S; Castells A; Rubini M; Gascón P; Maurel J
    Cancer Biol Ther; 2011 Jan; 11(2):177-83. PubMed ID: 21099348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
    Cappuzzo F; Varella-Garcia M; Finocchiaro G; Skokan M; Gajapathy S; Carnaghi C; Rimassa L; Rossi E; Ligorio C; Di Tommaso L; Holmes AJ; Toschi L; Tallini G; Destro A; Roncalli M; Santoro A; Jänne PA
    Br J Cancer; 2008 Jul; 99(1):83-9. PubMed ID: 18577988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.
    Martin V; Landi L; Molinari F; Fountzilas G; Geva R; Riva A; Saletti P; De Dosso S; Spitale A; Tejpar S; Kalogeras KT; Mazzucchelli L; Frattini M; Cappuzzo F
    Br J Cancer; 2013 Feb; 108(3):668-75. PubMed ID: 23348520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
    Frattini M; Saletti P; Romagnani E; Martin V; Molinari F; Ghisletta M; Camponovo A; Etienne LL; Cavalli F; Mazzucchelli L
    Br J Cancer; 2007 Oct; 97(8):1139-45. PubMed ID: 17940504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.